Shares of Novo Nordisk dropped over 24% after disappointing results in a trial for its CagriSema weight loss drug, which fell short of expectations with a 22.7% weight reduction. The stock recovered slightly to trade down 18.8%, while rival Eli Lilly’s obesity drug saw a 5% rise. Novo plans to further explore CagriSema’s potential after outperforming Wegovy in weight loss, with regulatory submission expected by 2025.
Full Article
US judge finds probable cause to hold Trump officials in contempt over alien act deportations | Trump administration
A federal judge determined on Wednesday that there is probable cause to hold Trump officials in contempt for breaching a temporary injunction that prohibited the application of the Alien Enemies Act to deport suspected Venezuelan gang members. This ruling highlights ongoing legal challenges surrounding the treatment of foreign nationals under wartime powers. Further details regarding the implications of this decision and the actions of the officials involved are expected to be released shortly. Full Article
Read more